Top 10 Life Sciences Stocks To Buy Right Now

Top 10 Life Sciences Stocks To Buy Right Now: NPS Pharmaceuticals Inc.(NPSP)

NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company?s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.

Advisors' Opinion:

• [By Keith Speights]

  Two high-flying biotech stocks of late are NPS Pharmaceuticals (NASDAQ: NPSP  ) and Regeneron Pharmaceuticals (NASDAQ: REGN  ) . Both have had great results over the past month.

• [By Louis Navellier]

  SVA is a strong buy at the current price.

  Biotech Stocks to Buy: NPS Pharmaceuticals (NPSP)

  NPS Pharmacuticals (NPSP) currently has five drugs for things like osteoporosis, hyperparathyroidism, pain management and short bowel syndrome. They focus their research efforts right now on things like gastrointestinal, psychiatric, neurological and bone and mineral disorders. The company had triple digit gains in sales and earnings in the most recent quarter and the strong fundamentals were noticed by Portfolio Grader.

• [By RichardCox]

  Investing in biotech can seem intimidating, given the complex nature of the industry. So, for those looking for a simple way to gain exposure to the industry, a basket sector ETF might be the best choice. The! clearest option here is the SPDR S&P Biotech ETF (XBI), which has nominal gross expense ratio of 0.35% and an average return of nearly 10% since it was started in 2006. The fund's holdings include Sarepta Therapeutics (SRPT), which has made well-documented progress in Eteplirsen, its Duchenne muscular dystrophy drug. Most analysts expect Eteplirsen to receive relatively quick FDA approval, helping support the underlying value of the stock. Other holdings include NPS Pharmaceuticals (NPSP), which recently bought back the right to Gattex, a short bowel syndrome drug.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-life-sciences-stocks-to-buy-right-now.html